Pacemaker-Mediated Programmable Hypertension Control Therapy.
Petr Neuzil, Béla Merkely, Andrejs Erglis...
https://pubmed.ncbi.nlm.nih.gov/29275370/Actively Recruiting
Led by Orchestra BioMed, Inc · Updated on 2026-10-02
316
Participants Needed
131
Research Sites
139 weeks
Total Duration
Researchers are evaluating a new atrioventricular interval modulation AVIM algorithm programmed into a dual-chamber Medtronic AstraAzure pacemaker. This trial is designed to assess the safety and effectiveness of this device-based therapy in patients who have hypertension and either already have or need a dual-chamber pacemaker. The study is randomized, double-blind, and conducted across multiple countries. The study has three phases an initial screening phase, followed by a one-year double-blind randomized phase where participants are assigned to either have the AVIM therapy turned on or off, while continuing their stable antihypertensive medication. After this, there is a two-year unblinded phase for further observation. The investigational AVIM therapy is delivered through the pacemaker device. Participants will be monitored for changes in their 24-hour ambulatory systolic blood pressure and for any unexpected serious adverse effects related to the device. Assessments will be done at baseline and three months after randomization, with ongoing evaluation during the two-year follow-up. The entire study duration can last up to three years, including screening and all treatment phases.
CONDITIONS
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
S
Steven J. Evans, MD
A
Angela Stagg
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Orchestra BioMed, Inc
Lead Sponsor
Medtronic
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | AVIM‑activated pacemaker | Pacemaker without AVIM therapy |
|---|---|---|
| What it is | A dual‑chamber pacemaker system delivering atrioventricular interval modulation (AVIM) therapy to lower blood pressure | The same pacemaker system with AVIM therapy deactivated as a sham comparator |
| Role in trial | Investigational arm receiving active AVIM pacing therapy | Control arm with deactivated AVIM, serving as sham comparator |
| Primary use | To lower ambulatory systolic blood pressure by pacing‑based AV interval modulation | To serve as control for comparison of blood pressure effect |
| How it is given or performed | Activated AVIM algorithm via implanted dual‑chamber pacemaker | Same implantable device without AVIM algorithm activated |
| Evidence status | Pilot and early data show reductions in 24‑hour systolic blood pressure (~8 mmHg at 6 months) and improved cardiac hemodynamics in small studies | No effect on blood pressure expected when AVIM therapy is deactivated |
| Important risks | Safety being assessed; unanticipated serious adverse device effects monitored for first 3 months | Safety monitored similarly to experimental arm |
| Important limitations | Evidence currently limited to small early studies; long‑term efficacy and broader applicability still under investigation | Sham comparator does not represent current standard care for hypertension beyond device implantation |
| Patient impact | May reduce ambulatory systolic blood pressure modestly in patients with pacemaker indications | No expected blood pressure benefit |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 30 days before or any time after pacemaker implant
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - 1 year
Participants are randomly assigned to have AVIM therapy activated or deactivated in their pacemaker while continuing stable blood pressure medications.
Regular visits during the year
Duration - 2 years
Participants continue in an open phase where AVIM therapy status is known and monitored for two additional years.
Periodic visits during follow-up
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Petr Neuzil, Béla Merkely, Andrejs Erglis...
https://pubmed.ncbi.nlm.nih.gov/29275370/Zbigniew Kalarus, Béla Merkely, Petr Neužil...
https://pubmed.ncbi.nlm.nih.gov/34387126/Orchestra BioMed, Inc
Lead Sponsor
Medtronic
Collaborating Sponsor